BOSTON–(BUSINESS WIRE)–Karuna Therapeutics, Inc. today announced that it has previously
confidentially submitted a draft registration statement on Form S-1 with
the Securities and Exchange Commission (the “SEC”) relating to the
proposed initial public offering of its common stock. The number of
shares to be offered and the price range for the proposed offering have
not yet been determined. The initial public offering is expected to
commence after the SEC completes its review process, subject to market
and other conditions.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities. Any offers,
solicitations or offers to buy, or any sales of securities will be made
in accordance with the registration requirements of the Securities Act
of 1933, as amended (“Securities Act”). This announcement is being
issued in accordance with Rule 135 under the Securities Act.
Contacts
Investor Contact:
Chris Brinzey
Westwicke, an ICR
Company
+1 339 970-2843
chris.brinzey@westwicke.com
Media Contact:
Amanda Sellers
GlobalHealthPR
+1
404 865-3597
asellers@globalhealthpr.com
